Clonal Hematopoiesis, Hereditary Cancer Syndrome, Li-Fraumeni Syndrome, Mosaicism, TP53 Gene Mutation
Conditions
Keywords
Li-Fraumeni Syndrome, TP53 Gene Mutation (Variant), Hereditary Cancer Syndrome, Clonal Hematopoiesis, Mosaicism
Brief summary
The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g. ACE/CHIP and mosaicism).
Detailed description
This research study looks to enroll as many people with LFS or TP53 gene variants as possible in order to: * Better estimate cancer risks in individuals with TP53 variants or LFS, which is a rare condition. * Learn the range of cancer risks linked to TP53 variants to help individuals and families to improve our ability to counsel patients and families about cancer risks more accurately. * Improve opportunities for cancer prevention, early detection, and treatment. * Learn more about the meaning of TP53 variants in the blood that are not inherited (e.g. ACE/CHIP and mosaicism). Study procedures will include: * Collecting information from the participant's medical record and short questionnaires. * Collecting blood, saliva, eyebrow hair and tumor tissue samples (optional). * Sharing study information with family members (optional). It is expected that about 1500 people will take part in this research study. Participants will be in this study until it closes or the participant withdraws consent. The National Cancer Institute is providing funding for part of this study and is considered a study sponsor. They will require that some of the genetic information be made available to the research community without personal identifying information.
Interventions
GENETICData and Specimen Collection
* Provide research team and access to relevant medical records * Answer short questionnaires periodically * Consider consenting to other optional parts of the research such as: * Providing up to 3 tubes (15ml) of blood at or near the time of consent, as approved by treating physician (optional). * Provide a saliva sample (optional). * Provide eyebrow hairs for analysis of DNA from the bulb (15-20 eyebrow plucks) (optional). * Provide permission for obtainment of stored tissue specimens from cancer or pre-cancer surgeries or biopsies from the pathology departments where they have been stored (optional). * Consider inviting relatives to join the study (optional).
Sponsors
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
City of Hope Medical Center
Baylor College of Medicine
Study design
Observational model
FAMILY_BASED
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Individuals with a TP53 pathogenic or likely pathogenic variant identified in blood or saliva, * Individuals with variants of uncertain significance in TP53 may be eligible at the PI's discretion, * Blood relatives of individuals with a TP53 variant, who may be presumed obligate carriers or healthy controls, * Individuals who meet Classic or Chompret LFS criteria whether or not they have a TP53 gene variant, * Individuals may enroll their deceased relatives in the study. * Individuals with a known TP53 variant that is not LFS, but rather ACE, CHIP, or mosaicism. * Individuals participating in other LFS studies can still enroll in LiFT UP. Investigators may be collaborators.
Exclusion criteria
* Individuals who decline to sign consent * Individuals who are unable to give consent or assent and are without a designated healthcare proxy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Repository of specimens and data | 5 years or Study closure | Examine accuracy of family history and the extent to which families meet various published Li-Fraumeni family criteria or assess for de-novo mutations using descriptive statistics. Exact binomial confidence limits for percents will be calculated at 95% coverage. Tests of difference between \>2 groups for binary variables will use the Fisher exact test. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Estimation of Cancer Risks in TP53 mutation carriers | 5 years or Study closure | Estimate the frequency in ExAc as a population rate and calculate a standardized risk ratio as the ratio of the prevalence of mutations in a given cancer type compared to that in ExAc. P-values and 95% confidence intervals will be calculated assuming the observed number of mutations follows a Poisson distribution with mean equal to the expected value calculated from the ExAC observed frequency. |
| Modified segregation analysis | 5 years or Study closure | For each dataset, the following analyses will be performed using MENDEL: a) the relative risk (RR) across age groups is assumed to be constant; b) the RR is assumed to be a continuous, piece wise linear function of age which was constant before age 40 years and after age 60 years, and linear between ages 40 and 60 years |
| Estimation of risk for the more commonly occurring cancers associated with inherited TP53 mutations | 5 years or Study closure | P-values and 95% confidence intervals will be calculated |
Countries
United States
Contacts
CONTACTJudy E Garber, MD, MPH
CONTACTSophie Cahill, BS
PRINCIPAL_INVESTIGATORJudy E Garber, MD, MPH
Dana-Farber Cancer Institute
Outcome results
None listed